Analysis of Antibody Markers as Immune Correlates of Risk of Severe COVID-19 in the PREVENT-19 Efficacy Trial of the NVX-CoV2373 Recombinant Protein Vaccine

Post-vaccination NVX-CoV2373 antibody levels are stronger predictors of severe COVID-19 than any-severity Delta COVID-19. Low antibody responses indicate vulnerability to severe COVID-19.

Authors

Institutions

Publication Details

Journal
Clinical Infectious Diseases
Published
2025-10-14
DOI
https://doi.org/10.1093/cid/ciaf558
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Analysis of Antibody Markers as Immune Correlates of Risk of Severe COVID-19 in the PREVENT-19 Efficacy Trial of the NVX-CoV2373 Recombinant Protein Vaccine

Rubén O. Donis, Alice McGarry, Michele P. Andrasik, Yunda Huang et al.
Clinical Infectious Diseases
SARS-CoV-2 and COVID-19 Research
article

Analysis of Antibody Markers as Immune Correlates of Risk of Severe COVID-19 in the PREVENT-19 Efficacy Trial of the NVX-CoV2373 Recombinant Protein Vaccine

Rubén O. Donis, Alice McGarry, Michele P. Andrasik, Yunda Huang, Flora Castellino, Richard A. Koup, Christopher R. Houchens, Christine B. Turley, Ying Huang, Iksung Cho, Thomas Jones, Maryam Keshtkar‐Jahromi, James G. Kublin, April K. Randhawa, Lakshmi Jayashankar, Christos J. Petropoulos, Wayne Woo, Cynthia L. Gay, Kathleen M. Neuzil, Yiwen Lu, Julie A. Ake, Karen Martins, Dean A. Follmann, Tatiana Beresnev, Lawrence Corey, Milagritos D. Tapia, Chenchen Yu, Deanne Haugaard, Youyi Fong, Elizabeth Barranco, Germán Áñez, Andrew Leith, Lisa M. Dunkle, Peter B. Gilbert, Lindsay Nicole Carpp, Julia Hütter, Carina A. Rodriguez, Susan E Kline, Karen L. Kotloff, Carmen Zorrilla, William A. Webb, Stuart H. Cohen
article en

Abstract

Post-vaccination NVX-CoV2373 antibody levels are stronger predictors of severe COVID-19 than any-severity Delta COVID-19. Low antibody responses indicate vulnerability to severe COVID-19.

Clinical Infectious Diseases
University of North Carolina at Charlotte (US), University of North Carolina at Chapel Hill (US), University of Maryland, Baltimore (US), National Institutes of Health (US), Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa (ZA), Minneapolis Institute of Arts (US), Infectious Disease Research Institute (US), University of Puerto Rico, Medical Sciences Campus (PR), Ponce Health Sciences University (PR), University of Washington (US), University of South Florida (US), Biomedical Advanced Research and Development Authority (US), LabCorp (United States) (US), University of Puerto Rico at Ponce (PR), Fred Hutch Cancer Center (US), Communities In Schools of Orange County (US), Novavax (United States) (US), Cancer Research And Biostatistics (US), Atrium Medical Cente (US), National Institute of Allergy and Infectious Diseases (US), University of Minnesota Medical Center (US), University of Washington Applied Physics Laboratory (US), University of California Davis Medical Center (US), California State University, Sacramento (US), Seattle University (US), University of Baltimore (US), Exelis (United States) (US), Walter Reed Army Institute of Research (US), University of Tampa (US)
Openalex Percentile: Top 64%
SARS-CoV-2 and COVID-19 Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.